Journal: Oncotarget

Article Title: CXCL8 derived from tumor-associated macrophages and esophageal squamous cell carcinomas contributes to tumor progression by promoting migration and invasion of cancer cells

doi: 10.18632/oncotarget.22526

Figure Lengend Snippet: (A) The mRNA level of CXCL8 in PBMo-derived macrophages stimulated with 50% TECM or 50% Het-1A CM was determined by quantitative RT-PCR. The data were normalized to GAPDH as an internal control. Data are mean ± SEM in triplicate. ** p < 0.01, **** p < 0.0001. (B) Expression of CXCL8 in PBMo-derived macrophages stimulated with TECM or Het-1A CM was confirmed by immunofluorescence using anti-CXCL8 antibody (green). Nuclei were stained with DAPI (blue). Magnification × 400. Scale bar, 50 μm. (C) Concentration of CXCL8 protein in conditioned medium of PBMo-derived macrophages stimulated with TECMs and ESCC cell lines. Protein levels were measured by ELISA. RPMI, negative control RPMI-1640 medium with serum. Data are mean ± SEM in triplicate. *** p < 0.001.

Article Snippet: After 48 h, the CXCL8 levels in the cell culture supernatants were determined by the Quantikine ELISA Human IL-8 immunoassay (R&D Systems) according to the manufacturer's instructions.

Techniques: Derivative Assay, Quantitative RT-PCR, Control, Expressing, Immunofluorescence, Staining, Concentration Assay, Enzyme-linked Immunosorbent Assay, Negative Control

Journal: Scientific reports

Article Title: Blood-brain barrier and gut barrier dysfunction in chronic kidney disease with a focus on circulating biomarkers and tight junction proteins.

doi: 10.1038/s41598-022-08387-7

Figure Lengend Snippet: Figure 2. Analysis of soluble CD14 (sCD14) levels in haemodialysis (HD) and non-CKD controls (control). (A) Soluble CD14 levels. The number of samples (n) that each analyte was detected in is noted for each group. Data presented at median and interquartile range. Statistical significance, ***p < 0.001, ****p < 0.0001. (B) Spearman’s correlation between sCD14 and trimethylamine N-oxide (TMAO) levels.

Article Snippet: The S100B ELISA kit was performed in accordance with manufacturer guidelines, with the alteration that samples were undiluted. sCD14 levels in HD patients was previously recorded and reported87, for measurements in non-CKD controls the same CD14 ELISA kit (DC140, R&D Systems, UK) was used, and run in accordance with manufacturer guidelines.

Techniques: Control

Journal: Scientific reports

Article Title: Blood-brain barrier and gut barrier dysfunction in chronic kidney disease with a focus on circulating biomarkers and tight junction proteins.

doi: 10.1038/s41598-022-08387-7

Figure Lengend Snippet: Figure 1. Analysis of serum biomarkers in haemodialysis (HD) and non-CKD controls (control). (A) Brain-derived neurotrophic factor (BDNF), (B) Neuron-specific enolase (NSE) were measured by enzyme- linked immunosorbent assay (ELISA). (C) Trimethylamine N-oxide (TMAO) was measured by liquid chromatography-mass spectrometry (LC–MS). The number of samples (n) that each analyte was detected in is noted for each group. Data presented at median and interquartile range. Statistical significance, ***p < 0.001, ****p < 0.0001. (D) Spearman’s correlation between BDNF and TMAO levels. (E) Spearman’s correlation between NSE and TMAO levels.

Article Snippet: The S100B ELISA kit was performed in accordance with manufacturer guidelines, with the alteration that samples were undiluted. sCD14 levels in HD patients was previously recorded and reported87, for measurements in non-CKD controls the same CD14 ELISA kit (DC140, R&D Systems, UK) was used, and run in accordance with manufacturer guidelines.

Techniques: Control, Derivative Assay, Enzyme-linked Immunosorbent Assay, Liquid Chromatography, Mass Spectrometry, Liquid Chromatography with Mass Spectroscopy